Therefore, we suggest that the traditional practice of peritoneal closure be abolished in gynecology and obstetrics. It is our strong wish to encourage clinicians not to close both parietal and visceral peritoneum.

No abstract

Bladder carcinomas are common medical problem of modern society. They represent second most common malignancy of genito-urinary sistem. Rhabdomyosarcoma is on of most common soft tissue tumor in infants and children, arising from immature cells destined to differentiate into striated muscle cells. On the other hand, bladder rhabdomyosarcomas in the adult population are extremely rare and so far only few cases are described in literature. We present a patient in the seventh decade of life, successfully operated from a rare type of embryonic bladder rhabdomyosarcoma, botrioid subtype.

Prostate cancer is the second most common cause of cancer mortality in men population. Multifactorial etiology, unpredictable course and outcome of the disease put survival determining factors of disease in the spotlight. One of new survival prognostic factors is Charlson Comorbidity Index-CCI. We presented basic characteristics of CCI, literature review regarding the CCI, as well as advantages and disadvantages of this index. CCI represents optimal balance between ease of use and prognostic capabilities. CCI value significantly contributes to better assessment of the long-term survival and the selection of appropriate cancer therapy.

ApstraktKarcinom mokraćne bešike predstavlja načešći malignitet urinarnog trakta. Primarni standardni tretman tumora mokraćne bešike je transuretralna resekcija (TUR), ali procenat recidiva kod pacijenata tretiranih samo TUR-om je do 70%, a procenat progresije tumora tj, invazije u mišićni sloj je oko 30%, a to su pacijenti kojima je indikovano radikalno operativno leče-nje. Intravezikalna instalacija bacillus Calmette-Guerin (BCG) nakon TUR tumora mokraćne bešike predstavlja dokazano najefikasnije pomoćno sredstvo u lečenju i profilaksi površinskih karcinoma mokraćne bešike. Cilj našeg rada je poređenje ishoda lečenja pacijenata podvrgnutih TUR sa pacijentima lečenim kombinovanom terapijom koja obuhvata sprovođenje imunoterapije intravezikalnom instalacijom BCG nakon TUR. Rezltati prikazani u radu predstavljaju izvod rezultata prospektivno-retrospektivne studije koja se od januara 2013. godine sprovodi na odeljenju Urologije KBC Zemun. AbstractBladder cancer is the most common malignancy of the urinary tract. The primary standard treatment of the bladder tumors is transurethral resection (TUR), however the percentage of relapse in patients treated with TUR only is up to 70%, and the percentage of tumor progression (invasion of muscle layer) is about 30%. In these patients radical surgical treatment is indicated. Intravesical Bacillus Calmette-Guerin (BCG) installation after TUR of bladder tumors is the most effective support treatment of superficial bladder cancers.The aim of our study was to compare treatment outcomes of patients undergoing TUR to patients treated with combined therapy (BCG immunotherapy after TUR). Results presented in this paper are extracted results of a prospective -retrospective study which is carried out and ongoing at Urology department in Clinical Hospitel Zemun since january 2013.Ključne reči: bladder cancer; bacillus CalmetteGuerin; immunotherapy UvodKarcinom mokraćne bešike predstavlja načešći malignitet urinarnog trakta. Javlja se skoro tri puta češće kod muškaraca 1, 2 . Procenjena ukupna petogodišnja prevalenca na nivou svetske populacije iznosi 1,110,265 slučajeva karcinoma mokraćne bešike. Prevalenca mišićno neinvazivnih karcinoma mokraćne bešike je oko deste puta veća od njihove incidence, zbog čega uopšteno karcinomi mokraćne bešike predstavljaju veliko ekonomsko opterećenje na zdravstvene sisteme. Zanimljiv je podatak da kumulativni troškovi po pacijentu od trenutka dijagnoze do smrti pacijenta čine karcinom mokraćne bešike najskupljim malignitetom za lečenje 3 . U 2002. godini odobrena je TNM klasifikacija (tumor/limfni čvor/metastaza) karcinoma mokraćne bešike od strane "the Union International Contre le Cancer", koja je široko prihvaćena. Iako je TNM klasifikacija